NovoCure Limited (NVCR) Earnings History
Net Loss13 years of earnings data (2013–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
NovoCure Limited (NVCR) Earnings Overview
As of June 21, 2026, NovoCure Limited (NVCR) reported trailing twelve-month net income of -$173M, reflecting +21.8% year-over-year growth. The company earned $-1.52 per diluted share over the past four quarters, with a net profit margin of -20.8%.
Looking at the long-term picture, NVCR's historical earnings data spans multiple years. The company achieved its highest annual net income of $20M in fiscal 2020.
NovoCure Limited is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including NKTR (-$158M net income, -297.1% margin), INVA ($504M net income, 63.8% margin), SUPN (-$29M net income, -5.4% margin), NVCR has outperformed on profitability metrics. Compare NVCR vs NKTR →
NVCR Earnings vs Peers
Earnings metrics vs comparable public companies
NVCR Historical Earnings Data (2013–2025)
13 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$136M | +19.2% | -$154M | $-1.22 | -20.8% | -23.5% |
| 2024 | -$169M | +18.6% | -$170M | $-1.56 | -27.9% | -28.2% |
| 2023 | -$207M | -123.7% | -$233M | $-1.95 | -40.6% | -45.7% |
| 2022 | -$93M | -58.6% | -$90M | $-0.88 | -17.2% | -16.6% |
| 2021 | -$58M | -394.6% | -$44M | $-0.56 | -10.9% | -8.3% |
| 2020 | $20M | +374.0% | $30M | $0.18 | 4.0% | 6.1% |
| 2019 | -$7M | +88.6% | $-914,000 | $-0.07 | -2.1% | -0.3% |
| 2018 | -$64M | -3.1% | -$34M | $-0.69 | -25.6% | -13.6% |
| 2017 | -$62M | +53.2% | -$39M | $-0.70 | -34.8% | -22.2% |
| 2016 | -$132M | -18.2% | -$115M | $-1.54 | -159.1% | -139.1% |
| 2015 | -$112M | -38.3% | -$104M | $-1.34 | -337.2% | -314.3% |
| 2014 | -$81M | -4.3% | -$80M | $-1.12 | -520.9% | -517.5% |
| 2013 | -$77M | - | -$64M | $-6.43 | -746.9% | -622.3% |
Download Data
Export NVCR earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
13+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
NVCR — Frequently Asked Questions
Quick answers to the most common questions about buying NVCR stock.
What is NVCR earnings per share (EPS)?
NVCR trailing twelve-month (TTM) diluted EPS is $-1.52, reflecting +21.8% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2013 to 2025 is available in the table on this page.
What is NovoCure Limited's net income?
NovoCure Limited (NVCR) trailing twelve-month net income is $-173M as of 2025. Earnings grew +21.8% year-over-year.
Is NVCR profitable?
NVCR is not currently profitable on a TTM basis, reporting a net loss of $-173M. Net margin is -20.8%. Investors should monitor for a return to profitability.
What is NVCR's earnings growth rate?
NVCR compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2013 to 2025.
What are NVCR's profit margins?
NovoCure Limited net profit margin is -20.8%, operating margin is -23.5%, and gross margin is +74.5%. Below-average margins reflect competitive or cost pressures. Return on Equity is -38.9%.
Is NVCR growing earnings?
Yes, NVCR earnings are accelerating — EPS growth of +21.8% exceeds the 5-year CAGR of N/A. TTM net income reached $-173M. Earnings momentum is strengthening.
What was NVCR's best earnings year?
NovoCure Limited's highest annual net income on record is $20M, achieved in fiscal year 2020. Earnings history on this page spans 2013 to 2025 and includes all annual and quarterly figures.
What were NVCR's earnings last quarter?
NVCR's most recent reported quarter was Q1 2026. Net income was $-71M with diluted EPS of $-0.62. For a full breakdown of all quarters, see the quarterly earnings table on this page.